Tebao Biotech announced that its wholly-owned subsidiary Xiamen Bosai Gene Transcription Technology Co., Ltd. plans to use its own funds to acquire part of Skyline Therapeutics Limited's assets. The transaction consideration includes a consolidated consideration of 15 million US dollars, and additional consolidated consideration consisting of payment of development and sales milestones of up to 43 million US dollars when the agreed conditions of the agreement are met, license commission and sales commission calculated as a single-digit percentage of annual net sales. After the transaction is completed, the target company will become a wholly-owned subsidiary of Bethai Gene and included in the scope of the company's consolidated statements.

Tebao Biotech announced that its wholly-owned subsidiary Xiamen Bosai Gene Transcription Technology Co., Ltd. plans to use its own funds to acquire part of Skyline Therapeutics Limited's assets. The transaction consideration includes a consolidated consideration of 15 million US dollars, and additional consolidated consideration consisting of payment of development and sales milestones of up to 43 million US dollars when the agreed conditions of the agreement are met, license commission and sales commission calculated as a single-digit percentage of annual net sales. After the transaction is completed, the target company will become a wholly-owned subsidiary of Bethai Gene and included in the scope of the company's consolidated statements.